Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II personalised mRNA vaccine PTX-108 for high-risk pediatric and young adult brain tumors
ACTRN12626001060336Phase 2Not yet recruiting
- Sponsor
- Australia & New Zealand Children’s Haematology and Oncology Group
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of PTX-108 in brain cancer, central nervous system tumor, diffuse midline glioma (DMG) and 2 more (3 arms), sponsored by Australia & New Zealand Children’s Haematology and Oncology Group. Primary endpoints: Composite progression-free survival and overall survival in Stratum A and Composite progression-free survival and overall survival in Stratum B. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
PTX-108
03
Conditions
brain cancercentral nervous system tumordiffuse midline glioma (DMG)medulloblastomaependymoma
Beyond the preview
Go deeper on ACTRN12626001060336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001060336.